Diabetes Australia has been advised that Fiasp insulin will be removed from the Pharmaceutical Benefits Scheme from 1 April 2023.

This means people will no longer be able to access it at a subsidised price. Fiasp will be available for people who choose to access it via private prescription; however, this will be more expensive.

We understand this is causing distress for some people living with diabetes who currently use this medication. We have conveyed our concerns to Novo Nordisk and the Government, and are continuing these discussions to see what can be done to reduce the impact on people living with diabetes who are using this medication.

In the meantime, if you are using Fiasp, we strongly encourage you to make an appointment with your doctor as soon as possible to discuss alternative insulins. If you have any questions or concerns, please contact Diabetes Australia on 1800 177 055.